Dr Joe Anderson commented: “From the inception of Arix, the goal was to build a listed life-sciences group investing in and supporting innovative young companies. The build stage of Arix has substantively been completed, and now offers access to a growing portfolio of highly innovative, fast-developing life-science companies, hitherto largely only available to private equity investors. Arix’s core business is in good shape and strongly positioned to deliver growth.  As Arix develops a strategy for its next phase of growth, it is appropriate to develop the leadership structure.  I look forward to focusing more on investment, company building and helping to drive continued value creation.”